Product
Moderna SARS-CoV-2 Vaccine
1 clinical trial
2 indications
Indication
Chronic Kidney DiseaseIndication
COVID-19Clinical trial
A Multi-Centre 12 Month Parallel-Group Randomized Control Trial of BNT162b2 Versus mRNA( Messenger Ribonucleic Acid) -1273 COVID-19 Vaccine Boosters in Chronic Kidney Disease and Dialysis Patients With Poor Humoral Response Following COVID-19 ( Corona Virus Disease of 2019)VaccinationStatus: Terminated, Estimated PCD: 2022-05-11